4 recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 2 | Recruiting 2 |
Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC irinotecan, cetuximab, envafolimab - RAS Mutation, Metastatic Colorectal Cancer | Phase 2 | Recruiting | Beijing Hospital | 60 | 2024-03-01 | 2026-07-28 |
| Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer Cadonilimab + bevacizumab + FOLFOX - Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma | Phase 2 | Recruiting | Fudan University | 53 | 2024-01-01 | 2024-01-23 |
Colorectal Neoplasms (2) · Lung Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Rectal Diseases (2) · Lung Diseases (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Cetuximab (2) · Irinotecan (2) · Bevacizumab (1) · Fluorouracil (1) · Folfox protocol (1) · Gemcitabine (1) · Immune Checkpoint Inhibitors (1) · Leucovorin (1) · Oxaliplatin (1) · Taxes (1) · envafolimab (1)
Beijing Hospital (1) · Fudan University (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Tango Therapeutics, Inc. (1)
China (3) · Australia (1) · United States (1)